Broad spectrum antiangiogenic treatment for ocular neovascular diseases

Ofra Benny, Kei Nakai, Takeru Yoshimura, Lauren Bazinet, James D. Akula, shintaro nakao, Ali Hafezi-Moghadam, Dipak Panigrahy, Pouya Pakneshan, Robert J. D'Amato

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Pathological neovascularization is a hallmark of late stage neovascular (wet) age-related macular degeneration (AMD) and the leading cause of blindness in people over the age of 50 in the western world. The treatments focus on suppression of choroidal neovascularization (CNV), while current approved therapies are limited to inhibiting vascular endothelial growth factor (VEGF) exclusively. However, this treatment does not address the underlying cause of AMD, and the loss of VEGF's neuroprotective can be a potential side effect. Therapy which targets the key processes in AMD, the pathological neovascularization, vessel leakage and inflammation could bring a major shift in the approach to disease treatment and prevention. In this study we have demonstrated the efficacy of such broad spectrum antiangiogenic therapy on mouse model of AMD.Methods and Findings: Lodamin, a polymeric formulation of TNP-470, is a potent broad-spectrum antiangiogenic drug. Lodamin significantly reduced key processes involved in AMD progression as demonstrated in mice and rats. Its suppressive effects on angiogenesis, vascular leakage and inflammation were studied in a wide array of assays including; a Matrigel, delayed-type hypersensitivity (DTH), Miles assay, laser-induced CNV and corneal micropocket assay. Lodamin significantly suppressed the secretion of various pro-inflammatory cytokines in the CNV lesion including monocyte chemotactic protein-1 (MCP-1/Ccl2). Importantly, Lodamin was found to regress established CNV lesions, unlike soluble fmslike tyrosine kinase-1 (sFlk-1). The drug was found to be safe in mice and have little toxicity as demonstrated by electroretinography (ERG) assessing retinal and by histology. Conclusions: Lodamin, a polymer formulation of TNP-470, was identified as a first in its class, broad- pectrum antiangiogenic drug that can be administered orally or locally to treat corneal and retinal neovascularization. Several unique properties make Lodamin especially beneficial for ophthalmic use. Our results support the concept that broad spectrum antiangiogenic drugs are promising agents for AMD treatment and prevention.

Original languageEnglish
Article numbere12515
Pages (from-to)1-14
Number of pages14
JournalPloS one
Volume5
Issue number9
DOIs
Publication statusPublished - Nov 1 2010
Externally publishedYes

Fingerprint

eye diseases
Eye Diseases
angiogenesis
Macular Degeneration
Choroidal Neovascularization
Assays
Pathologic Neovascularization
drugs
Pharmaceutical Preparations
Therapeutics
lesions (animal)
therapeutics
Corneal Neovascularization
Retinal Neovascularization
Histology
assays
Inflammation
Chemokine CCL2
inflammation
Electroretinography

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Benny, O., Nakai, K., Yoshimura, T., Bazinet, L., Akula, J. D., nakao, S., ... D'Amato, R. J. (2010). Broad spectrum antiangiogenic treatment for ocular neovascular diseases. PloS one, 5(9), 1-14. [e12515]. https://doi.org/10.1371/journal.pone.0012515

Broad spectrum antiangiogenic treatment for ocular neovascular diseases. / Benny, Ofra; Nakai, Kei; Yoshimura, Takeru; Bazinet, Lauren; Akula, James D.; nakao, shintaro; Hafezi-Moghadam, Ali; Panigrahy, Dipak; Pakneshan, Pouya; D'Amato, Robert J.

In: PloS one, Vol. 5, No. 9, e12515, 01.11.2010, p. 1-14.

Research output: Contribution to journalArticle

Benny, O, Nakai, K, Yoshimura, T, Bazinet, L, Akula, JD, nakao, S, Hafezi-Moghadam, A, Panigrahy, D, Pakneshan, P & D'Amato, RJ 2010, 'Broad spectrum antiangiogenic treatment for ocular neovascular diseases', PloS one, vol. 5, no. 9, e12515, pp. 1-14. https://doi.org/10.1371/journal.pone.0012515
Benny O, Nakai K, Yoshimura T, Bazinet L, Akula JD, nakao S et al. Broad spectrum antiangiogenic treatment for ocular neovascular diseases. PloS one. 2010 Nov 1;5(9):1-14. e12515. https://doi.org/10.1371/journal.pone.0012515
Benny, Ofra ; Nakai, Kei ; Yoshimura, Takeru ; Bazinet, Lauren ; Akula, James D. ; nakao, shintaro ; Hafezi-Moghadam, Ali ; Panigrahy, Dipak ; Pakneshan, Pouya ; D'Amato, Robert J. / Broad spectrum antiangiogenic treatment for ocular neovascular diseases. In: PloS one. 2010 ; Vol. 5, No. 9. pp. 1-14.
@article{782562948fd747dcb6c38019f08ae367,
title = "Broad spectrum antiangiogenic treatment for ocular neovascular diseases",
abstract = "Pathological neovascularization is a hallmark of late stage neovascular (wet) age-related macular degeneration (AMD) and the leading cause of blindness in people over the age of 50 in the western world. The treatments focus on suppression of choroidal neovascularization (CNV), while current approved therapies are limited to inhibiting vascular endothelial growth factor (VEGF) exclusively. However, this treatment does not address the underlying cause of AMD, and the loss of VEGF's neuroprotective can be a potential side effect. Therapy which targets the key processes in AMD, the pathological neovascularization, vessel leakage and inflammation could bring a major shift in the approach to disease treatment and prevention. In this study we have demonstrated the efficacy of such broad spectrum antiangiogenic therapy on mouse model of AMD.Methods and Findings: Lodamin, a polymeric formulation of TNP-470, is a potent broad-spectrum antiangiogenic drug. Lodamin significantly reduced key processes involved in AMD progression as demonstrated in mice and rats. Its suppressive effects on angiogenesis, vascular leakage and inflammation were studied in a wide array of assays including; a Matrigel, delayed-type hypersensitivity (DTH), Miles assay, laser-induced CNV and corneal micropocket assay. Lodamin significantly suppressed the secretion of various pro-inflammatory cytokines in the CNV lesion including monocyte chemotactic protein-1 (MCP-1/Ccl2). Importantly, Lodamin was found to regress established CNV lesions, unlike soluble fmslike tyrosine kinase-1 (sFlk-1). The drug was found to be safe in mice and have little toxicity as demonstrated by electroretinography (ERG) assessing retinal and by histology. Conclusions: Lodamin, a polymer formulation of TNP-470, was identified as a first in its class, broad- pectrum antiangiogenic drug that can be administered orally or locally to treat corneal and retinal neovascularization. Several unique properties make Lodamin especially beneficial for ophthalmic use. Our results support the concept that broad spectrum antiangiogenic drugs are promising agents for AMD treatment and prevention.",
author = "Ofra Benny and Kei Nakai and Takeru Yoshimura and Lauren Bazinet and Akula, {James D.} and shintaro nakao and Ali Hafezi-Moghadam and Dipak Panigrahy and Pouya Pakneshan and D'Amato, {Robert J.}",
year = "2010",
month = "11",
day = "1",
doi = "10.1371/journal.pone.0012515",
language = "English",
volume = "5",
pages = "1--14",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Broad spectrum antiangiogenic treatment for ocular neovascular diseases

AU - Benny, Ofra

AU - Nakai, Kei

AU - Yoshimura, Takeru

AU - Bazinet, Lauren

AU - Akula, James D.

AU - nakao, shintaro

AU - Hafezi-Moghadam, Ali

AU - Panigrahy, Dipak

AU - Pakneshan, Pouya

AU - D'Amato, Robert J.

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Pathological neovascularization is a hallmark of late stage neovascular (wet) age-related macular degeneration (AMD) and the leading cause of blindness in people over the age of 50 in the western world. The treatments focus on suppression of choroidal neovascularization (CNV), while current approved therapies are limited to inhibiting vascular endothelial growth factor (VEGF) exclusively. However, this treatment does not address the underlying cause of AMD, and the loss of VEGF's neuroprotective can be a potential side effect. Therapy which targets the key processes in AMD, the pathological neovascularization, vessel leakage and inflammation could bring a major shift in the approach to disease treatment and prevention. In this study we have demonstrated the efficacy of such broad spectrum antiangiogenic therapy on mouse model of AMD.Methods and Findings: Lodamin, a polymeric formulation of TNP-470, is a potent broad-spectrum antiangiogenic drug. Lodamin significantly reduced key processes involved in AMD progression as demonstrated in mice and rats. Its suppressive effects on angiogenesis, vascular leakage and inflammation were studied in a wide array of assays including; a Matrigel, delayed-type hypersensitivity (DTH), Miles assay, laser-induced CNV and corneal micropocket assay. Lodamin significantly suppressed the secretion of various pro-inflammatory cytokines in the CNV lesion including monocyte chemotactic protein-1 (MCP-1/Ccl2). Importantly, Lodamin was found to regress established CNV lesions, unlike soluble fmslike tyrosine kinase-1 (sFlk-1). The drug was found to be safe in mice and have little toxicity as demonstrated by electroretinography (ERG) assessing retinal and by histology. Conclusions: Lodamin, a polymer formulation of TNP-470, was identified as a first in its class, broad- pectrum antiangiogenic drug that can be administered orally or locally to treat corneal and retinal neovascularization. Several unique properties make Lodamin especially beneficial for ophthalmic use. Our results support the concept that broad spectrum antiangiogenic drugs are promising agents for AMD treatment and prevention.

AB - Pathological neovascularization is a hallmark of late stage neovascular (wet) age-related macular degeneration (AMD) and the leading cause of blindness in people over the age of 50 in the western world. The treatments focus on suppression of choroidal neovascularization (CNV), while current approved therapies are limited to inhibiting vascular endothelial growth factor (VEGF) exclusively. However, this treatment does not address the underlying cause of AMD, and the loss of VEGF's neuroprotective can be a potential side effect. Therapy which targets the key processes in AMD, the pathological neovascularization, vessel leakage and inflammation could bring a major shift in the approach to disease treatment and prevention. In this study we have demonstrated the efficacy of such broad spectrum antiangiogenic therapy on mouse model of AMD.Methods and Findings: Lodamin, a polymeric formulation of TNP-470, is a potent broad-spectrum antiangiogenic drug. Lodamin significantly reduced key processes involved in AMD progression as demonstrated in mice and rats. Its suppressive effects on angiogenesis, vascular leakage and inflammation were studied in a wide array of assays including; a Matrigel, delayed-type hypersensitivity (DTH), Miles assay, laser-induced CNV and corneal micropocket assay. Lodamin significantly suppressed the secretion of various pro-inflammatory cytokines in the CNV lesion including monocyte chemotactic protein-1 (MCP-1/Ccl2). Importantly, Lodamin was found to regress established CNV lesions, unlike soluble fmslike tyrosine kinase-1 (sFlk-1). The drug was found to be safe in mice and have little toxicity as demonstrated by electroretinography (ERG) assessing retinal and by histology. Conclusions: Lodamin, a polymer formulation of TNP-470, was identified as a first in its class, broad- pectrum antiangiogenic drug that can be administered orally or locally to treat corneal and retinal neovascularization. Several unique properties make Lodamin especially beneficial for ophthalmic use. Our results support the concept that broad spectrum antiangiogenic drugs are promising agents for AMD treatment and prevention.

UR - http://www.scopus.com/inward/record.url?scp=77958536326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958536326&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0012515

DO - 10.1371/journal.pone.0012515

M3 - Article

VL - 5

SP - 1

EP - 14

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e12515

ER -